Emphycorp Press Releases

PRESS RELEASES

To read and or download the pdf articles click on the links below.

November 13, 2024 – EmphyCorp Press Release: Seeking a Collaboration Partner for an Expanded Phase III for Long COVID.

July 11, 2024 – EmphyCorp Press Release: Rx N115 Nonsteroidal Nasal Spray Expanded Phase III Clinical Trial results showed a 73% reduction in Coughing and clinically significant Improved Lung Function in Patients with Idiopathic Pulmonary Fibrosis (IPF).

March 7, 2024 – EmphyCorp Press Release Expanded Long COVID Phase III

December 1 2020 – Sodium Pyruvate Ameliorates Influenza A Virus Infection In Vivo _ Peer Review bioRxiv

April 7, 2020 – EmphyCorp N115 News: Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide

March 24, 2020 – EmphyCorp News: As Reported in The Lancet – Clinical Features of Patients Infected with the 2019 novel Coronavirus in Wuhan, China

March 17, 2020 – EmphyCorp News: Nitric Oxide is currently being tested in Clinical Trials as a Potential Treatment for Patients infected with the Coronavirus

J anuary 21, 2020 – EmphyCorp N115 Rx Globally Patented Non-Steroidal Nasal Spray with No Known Side Effects for Pregnant Women with Allergic Rhinitis or Asthma

January 14, 2020 – Rx Globally Patented Non-Steroidal Nasal Spray for All Lung Diseases including Pulmonary Fibrosis, CF, COPD, Unmet Needs with No Known Side Effects that can also be used to Deliver Antivirals, Antimicrobials, Insulin, and other Drugs

August 15, 2019 – EmphyCorp Inc. FDA Submission for Rx New Non-Steroidal Nasal Spray for Pulmonary Fibrosis w/ No Known Side Effects